Erasca, Inc.
ERAS Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$15.22
KIRA · Stoqly’s AI analyst, in plain words
- Erasca, Inc. lost $125M in fiscal 2025.
- Free cash flow was −$95.6M in fiscal 2025, — of revenue.
Market cap
$4.7B
P/E
—
Revenue
—
Net income
−$125M
Free cash flow
−$95.6M
Operating margin
—
Erasca, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$125M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Erasca, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Erasca, Inc.
- CIK
- 0001761918
Erasca, Inc. · ERAS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$123M | −$243M | −$125M | −$162M | −$125M |
| Diluted EPS | −$1.85 | −$1.99 | −$0.83 | −$0.69 | −$0.44 |
| Cash | |||||
| Cash from operations | −$79.6M | −$103M | −$101M | −$109M | −$95.5M |
| Capital expenditure | $11.2M | $14.6M | $1.8M | $0.1M | $0.1M |
| Free cash flow | −$90.8M | −$118M | −$103M | −$109M | −$95.6M |
| Share count change | 215.1% | 84.1% | 23.1% | 55.7% | 21.3% |
| Debt and strength | |||||
| Cash and short-term investments | $414M | $436M | $312M | $298M | $276M |
| Shareholders' equity | $457M | $412M | $317M | $423M | $325M |
| Current ratio | 16.0x | 9.1x | 12.3x | 9.8x | 10.0x |
| Returns and quality | |||||
| Return on equity | −71.7% | −55.9% | −34.3% | −43.7% | −33.3% |
| Return on tangible equity | −26.9% | −59.0% | −39.5% | −38.2% | −38.3% |
| Altman Z'' | 12.6 | 3.0 | 1.7 | 1.9 | −0.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$2.3M
2 insiders
Of sales under plans
100%
$2.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Erasca, Inc. · ERAS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $15.22 a share, the company is worth $4.7B.
Source: SEC EDGAR XBRL filings (CIK 0001761918). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.